Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease

Respirology

Volumn 16, Issue 1, 2011, Pages 95-101

  Hoshino, Makoto ^a   Ohtawa, Junichi ^a  

^a International University of Health and Welfare   (Japan)

Author keywords

Airway luminal area; Airway wall thickness; Chronic obstructive pulmonary disease; Fluticasone propionate; Salmeterol; Tiotropium

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; TIOTROPIUM BROMIDE;

AGED; AIRWAY; ARTICLE; BODY SURFACE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; LUNG FUNCTION; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT PARAMETERS;

AGED; AGED, 80 AND OVER; ALBUTEROL; ANDROSTADIENES; BRONCHI; BRONCHODILATOR AGENTS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 79952262390     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01869.x     Document Type: Article

References (36)

1. Hogg JC, Chu F, Utokaparch S et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 2645-53. (Pubitemid 38787999)
2. Rabe KF, Hurd S, Anzueto A et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007; 176: 532-55. (Pubitemid 47403272)
3. Global strategy for the diagnosis, management, and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). [Accessed April 2009.] Available from URL: http://www.goldcopd.org/
4. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543-54.
5. Barnes NC, Qiu YS, Pavord ID et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 736-43.
6. Mahler DA, Wire P, Horstman D et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166: 1084-91. (Pubitemid 35178706)
7. Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775-89. (Pubitemid 46294610)
8. Hanania NA, Darken P, Horstman D et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124: 834-43. (Pubitemid 37123298)
9. Ferguson GT, Anzueto A, Fei R et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir. Med. 2008; 102: 1099-108.
10. Aaron SD, Vandemheen KL, Fergusson D et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545-55. (Pubitemid 351650535)
11. Cazzola M, Andò F, Santus P et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-tovery severe COPD. Pulm. Pharmacol. Ther. 2007; 20: 556-61. (Pubitemid 47077647)
12. Nakano Y, Muro S, Sakai H et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am. J. Respir. Crit. Care Med. 2000; 162: 1102-8.
13. Hasegawa M, Nasuhara Y, Onodera Y et al. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 173: 1309-15. (Pubitemid 43900704)
14. Thurlbeck WM, Müller NL. Emphysema: definition, imaging, and quantification. Am. J. Roentgenol. 1994; 163: 1017-25. (Pubitemid 24355686)
15. Foster WL Jr, Pratt PC, Roggli VL et al. Centrilobular emphysema: CT-pathologic correlation. Radiology 1986; 159: 27-32. (Pubitemid 16112185)
16. Bergin C, Müller N, Nichols DM et al. The diagnosis of emphysema. A computed tomographic-pathologic correlation. Am. Rev. Respir. Dis. 1986; 133: 541-6. (Pubitemid 16127234)
17. Nakano Y, Wong JC, de Jong PA et al. The prediction of small airway dimensions using computed tomography. Am. J. Respir. Crit. Care Med. 2005; 171: 142-6. (Pubitemid 40105413)
18. Orlandi I, Moroni C, Camiciottoli G et al. Chronic obstructive pulmonary disease: thin-section CT measurement of airway wall thickness and lung attenuation. Radiology 2005; 234: 604-10. (Pubitemid 40139937)
19. Jones PW, Quirk FH, Baveystock CM et al. A self-complete measure for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am. Rev. Respir. Dis. 1992; 145: 1321-7.
20. Okazawa M, Müller N, McNamara AE et al. Human airway narrowing measured using high resolution computed tomography. Am. J. Respir. Crit. Care Med. 1996; 154: 1557-62. (Pubitemid 26391213)
21. Bourbeau J, Christodoulopoulos P, Maltais F et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007; 62: 938-43. (Pubitemid 350084490)
22. Laitinen A, Altraja A, Kämpe M et al. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am. J. Respir. Crit. Care Med. 1997; 156: 951-8. (Pubitemid 27396441)
23. Olivieri D, Chetta A, Del Donno M et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am. J. Respir. Crit. Care Med. 1997; 155: 1864-71. (Pubitemid 27256110)
24. Trigg CJ, Manolitsas ND, Wang J et al. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am. J. Respir. Crit. Care Med. 1994; 150: 17-22. (Pubitemid 24209930)
25. Hoshino M, Takahashi M, Takai Y et al. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J. Allergy Clin. Immunol. 1999; 104: 356-63. (Pubitemid 29420433)
26. Sont JK, Willems LN, Bel EH et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am. J. Respir. Crit. Care Med. 1999; 159: 1043-51. (Pubitemid 29202534)
27. Niimi A, Matsumoto H, Amitani R et al. Effect of short-term treatment with inhaled corticosteroid on airway wall thickening in asthma. Am. J. Med. 2004; 116: 725-31. (Pubitemid 38622308)
28. Hashimoto M, Tanaka H, Abe S. Quantitative analysis of bronchial wall vascularity in the medium and small airways of patients with asthma and COPD. Chest 2005; 127: 965-72. (Pubitemid 40775530)
29. Calverley PM, Burge PS, Spencer S et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659-64. (Pubitemid 36976273)
30. Tashkin DP, Celli B, Decramer M et al. Bronchodilator responsiveness in patients with COPD. Eur. Respir. J. 2008; 31: 42-50.
31. King GG, Carroll JD, Müller NL et al. Heterogeneity of narrowing in normal and asthmatic airways measured by HRCT. Eur. Respir. J. 2004; 24: 211-18. (Pubitemid 39139787)
32. Kaminsky DA, Irvin CG, Lundblad LK et al. Heterogeneity of bronchoconstriction does not distinguish mild asthmatic subjects from healthy controls when supine. J. Appl. Physiol. 2008; 104: 10-19.
33. Hasegawa M, Makita H, Nasuhara Y et al. Relationship between improved airflow limitation and changes in airway calibre induced by inhaled anticholinergic agents in COPD. Thorax 2009; 64: 332-8.
34. Singh D, Brooks J, Hagan G et al. Superiority of 'triple' therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63: 592-8. (Pubitemid 351969251)
35. Kim SJ, Im JG, Kim IO et al. Normal bronchial and pulmonary arterial diameters measured by thin section CT. J. Comput. Assist. Tomogr. 1995; 19: 365-9.
36. Gierada DS, Yusen RD, Pilgram TK et al. Repeatability of quantitative CT indexes of emphysema in patients evaluated for lung volume reduction surgery. Radiology 2001; 220: 448-54. (Pubitemid 32667183)